Nicolau J C, Ramires J A, Maggioni A P, Garzon S A, Pinto M A, Silva D G, Nogueira P R, Maia L F, Vendramini P, Bassi I
Instituto de Moléstias Cardiovasculares, Sao José do Rio Preto, Brazil.
Am J Cardiol. 1996 Nov 1;78(9):1049-52. doi: 10.1016/s0002-9149(96)00535-8.
The role of diltiazem on left ventricular systolic function was analyzed in 101 patients with acute myocardial infarction treated with streptokinase, being obtained, for the total of the population, higher LV global ejection fraction (p = 0.022), LV regional shortening (p = 0.046) and LV global shortening (p = 0.064) for the treated group, relative to the placebo group; the p values were, respectively, 0.005, 0.009, and 0.012, for patients that achieved TIMI-3 antegrade coronary flow. It is concluded that diltiazem is useful as adjuvant to streptokinase, especially when antegrade coronary blood flow TIMI-3 is obtained.
在101例接受链激酶治疗的急性心肌梗死患者中分析了地尔硫䓬对左心室收缩功能的作用。结果发现，与安慰剂组相比，治疗组患者总体的左心室整体射血分数更高（p = 0.022）、左心室节段缩短率更高（p = 0.046）、左心室整体缩短率更高（p = 0.064）；对于实现TIMI-3级冠状动脉前向血流的患者，p值分别为0.005、0.009和0.012。得出的结论是，地尔硫䓬作为链激酶的辅助药物是有用的，尤其是在获得TIMI-3级冠状动脉前向血流时。
